Objective To observe the therapeutic effect of ai-weizhi on anterior ischmic optic neuropathy (AION). Methods In 58 patients (60 eyes) who were diagnosed as with AION, 29 patients (30 eyes) underwent intravenous drip with ai-weizhi (1200 mg/d) (treatment group), and the other 29 patients (30 eyes) underwent intravenous drip with 1-2 kinds of thrombolytic coagulant or vasodilator (once per day) (control group) with the period of treatment of 15 days. In the control group, ocular local injection, including gluco-corticosteroid and 654-2 behind or beside the eyeball injected once per day or every 2 days for 3-5 times, was perfomed on 20 eyes simultaneously. The changes of visual acuity and ocular fundus of the patients after injection were recorded, and the visual field was counterchecked in the patients who had underwent the examination before the treatment. Results The visual acuity was better in treatment group than which in control group with a significant difference (t=2.74, Plt;0.01). The visual acuity in treatment group didnprime;t differ much from which in the control group 3 days after treatment (t=1.34, P＞0.05). At the 5th、10th and 15th day after treatment, the visual acuity was better in treatment group than which in control group with a significant difference(t=2.01, Plt;0.05; t=2.07, Plt;0.05；t=2.74, Plt;0.01). In 15 eyes in control group which had undergone examination of visual field, the visual field improved in 13 (87.00%) and of remained still in 2 (13.00%). In 13 eyes in treatment group which had undergone examination of visual field, the visual field improved in 4 (31.00%) and remained still in 9 (69.00%). There was a significant difference between the two groups (chi;2=9.66, Plt;0.01). Conclusion Ai-weizhi is efficacious in treatment of AION. (Chin J Ocul Fundus Dis, 2006, 22: 97-99)
Objective To analyze the clinical features of retinal detachment in macular spontaneous hemorrhage to improve the level of diagnosis and treatment of this disease. Methods The serial clinical data of 23 patients (23 eyes) with subretinal hemorrhage in macular region with the area over 4DDtimes;5DD who were diagnosed in our hospital from Sep, 1998 to Mar, 2003 were analyzed retrospectively. The patients included 12 males (12 eyes) and 11 females (11 eyes) with the average age of 64.1 (47-75). Fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA) and B-scan examination were performed on the patients to analyze the pathogenic factors, and the visual acuity and manifestation of ocular fundus were observed during the 8-24 months followed-up period. Results The visual acuity decreased to less than 0.2 or light perception suddenly in all affected eyes. In 23 eyes, choroidal neovascularization (CNV) of age-related macular degeneration (AMD) was found in 7, polypoidal choroidal vasculopathy (PCV) was in 5, retinal macroaneurysm was in 2, and unknow pathogenic factor in 9. Among the 23 eyes, hemorrhage was absorbed and no cicatritial formation at the fovea in 3 eyes with the visual acuity of 0.4-0.8; scar and pigment proliferation in the hemorrhage area were seen in 12 eyes with the visual acuity of finger counting (FC) to 0.2; combined vitreous hemorrhage was found in 8 eyes, including massive scar in the macular area in 3 who had undergone vitrectomy with the visual acuity of FC/66cm to 0.2 and blindness in the other 5 eyes. Conclusion Spontaneous hemorrhagic retinal detachment always arises in old people whose symptoms were sudden decrease or loss of the visual acuity. The configuration of the hemorrhage is local and diffuse. The prognosis of the visual acuity of most of the patients is poor due to the serious tissue injury in macula area. (Chin J Ocul Fundus Dis, 2006, 22: 228-231)
ObjectiveTo systematically review the renal adverse reactions of tyrosine kinase inhibitors (TKI). MethodsPubMed, EMbase, Cochrane Library, CNKI, WanFang Data and CBM databases were electronically searched to collect randomized controlled trials (RCTs) on the incidence of renal adverse reactions of TKI from inception to March 30, 2023. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was then performed by using RevMan 5.4 software. ResultsA total of 19 RCTs involving 10 141 patients were included. The results of meta-analysis showed that compared with placebo or blank control, gefitinib, ranvartinib, cabotinib, vandetanib, pazopanib, arotinib, apatinib, and acitinib could lead to an increased risk of proteinuria events, while sildenib did not increase the risk of proteinuria in patients. Anlotinib could increase the risk of hematuria. Vandetanil increased the risk of acute kidney injury. Gefitinib, ranvartinib and apatinib could increase the risk of grade 3-4 renal adverse reactions. ConclusionCurrent evidence shows that TKI drugs may cause renal damage in patients, and proteinuria is the most common. Vandetanil can cause acute kidney injury, gefitinib, ranvartinib and apatinib are more nephrotoxic. The renal adverse reactions of neratinib, ibutinib and sildenib are relatively few.